Foghorn Therapeutics Inc. expected to post a loss of 65 cents a share - Earnings Preview
06/05/2024 13:42
* Foghorn Therapeutics Inc. FHTX.OQ FHTX.O is expected
to show
a rise in quarterly revenue when it reports results on May 8
(estimated) for the period ending June 30 2024
* The Cambridge Massachusetts-based company is expected to
report
a 24.5% increase in revenue to $6.972 million from $5.6 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Foghorn Therapeutics
Inc. is
for a loss of 65 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 8.4%
in the last three months.
* Wall Street's median 12-month price target for Foghorn
Therapeutics Inc. is $14.50, above its last closing price
of $5.99.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.56 -0.63 -0.59 Beat 6.9
Dec. 31 2024 -0.94 -0.76 -0.57 Beat 25.3
Jan. 1 0001 -0.74 -0.75 -0.34 Beat 54.7
Jun. 30 2023 -0.74 -0.73 -0.70 Beat 4.8
Mar. -0.68 -0.72 -0.73 Missed -0.7
31 2023
Dec. 31 2022 -0.71 -0.62 -0.69 Missed -11.7
Jan. 1 0001 -0.67 -0.62 -0.62 Met 0
Jun. 30 2022 -0.65 -0.59 -0.66 Missed -11.4
This summary was machine generated May 6 at 12:42 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)